Welcome to our dedicated page for Avidity Biosciences news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Avidity Biosciences stock.
Avidity Biosciences, Inc. (Nasdaq: RNA) is a pioneering biopharmaceutical company dedicated to revolutionizing RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™). Their innovative approach merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases that were previously unreachable with existing RNA therapies. They are at the forefront of developing therapies for serious genetic conditions, predominantly focusing on rare muscle diseases.
Avidity's leading clinical programs include:
- AOC 1001 (Del-desiran): Targeting Myotonic Dystrophy Type 1 (DM1), a disease with no approved therapies. Del-desiran has shown promising long-term data from the MARINA-OLE™ trial, demonstrating reversal of disease progression in patients. The global Phase 3 HARBOR™ trial is set to begin, with video hand opening time (vHOT) as the primary endpoint.
- AOC 1044: Aimed at Duchenne Muscular Dystrophy (DMD) with mutations amenable to exon 44 skipping. Recently, it achieved Rare Pediatric Disease and Orphan Drug designations from the FDA and EMA. Positive preliminary data has been reported from the Phase 1/2 EXPLORE44™ clinical trial.
- AOC 1020: Focused on Facioscapulohumeral Muscular Dystrophy (FSHD). Clinical data from the Phase 1/2 FORTITUDE™ trial is expected soon.
Avidity is also advancing its pipeline to include cardiology and immunology programs, aiming to target a broader range of diseases. The company has garnered support and collaborations with top-tier investors and strategic partners, enhancing its capability to deliver groundbreaking treatments.
With headquarters in San Diego, CA, Avidity Biosciences is committed to transforming lives through innovative RNA therapeutics. For more information, visit www.aviditybiosciences.com.
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) partners with Bristol Myers Squibb (BMY) in a global licensing and research collaboration focused on cardiovascular targets. Avidity will receive $100 million upfront with the potential to receive up to $2.2 billion in milestone payments and up to low double-digit royalties. AOCs, Avidity's proprietary RNA therapeutics, will be utilized in the collaboration, expanding the reach of AOCs through the expansion of the existing relationship with Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) granted non-qualified stock options to purchase 27,000 shares of common stock and 13,500 restricted stock units to eight new non-executive employees under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $5.97 per share and will vest over four years, while the RSUs will vest in four equal installments on the first four anniversaries of the applicable vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
-
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) to Participate in 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
Rhea-AI Summary
Avidity Biosciences, Inc. (RNA) reported positive AOC 1001 data at World Muscle Society Congress, showing consistent improvement in functional endpoints and long-term safety in people with DM1. AOC 1044 received Orphan Designation for DMD in the US and EU. Avidity remains on track to report data from three clinical programs over the next nine months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
-
Rhea-AI Summary
Avidity Biosciences grants stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
-
Rhea-AI Summary
Avidity Biosciences announces positive data for AOC 1001 in treating myotonic dystrophy type 1 (DM1)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Avidity Biosciences will present at the 28th Annual Congress of the World Muscle Society, showcasing positive clinical trial data for AOC 1001 in Myotonic Dystrophy Type 1. The presentations will be available on Avidity's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary
Avidity Biosciences to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
-
Rhea-AI Summary
Avidity Biosciences grants non-qualified stock options and restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
Rhea-AI Summary
Avidity Biosciences, Inc. is joining patient communities to raise awareness during National Muscular Dystrophy Awareness Month. The company is advancing clinical development programs for three types of muscular dystrophy with planned data readouts over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
The current stock price of Avidity Biosciences (RNA) is $43.25 as of November 22, 2024.
What is the market cap of Avidity Biosciences (RNA)?
The market cap of Avidity Biosciences (RNA) is approximately 5.2B.
What is Avidity Biosciences, Inc.?
Avidity Biosciences, Inc. is a biopharmaceutical company pioneering RNA therapeutics with its proprietary Antibody Oligonucleotide Conjugates (AOCs™) to treat serious genetic diseases.
What are Antibody Oligonucleotide Conjugates (AOCs™)?
AOCs™ combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, enabling targeted treatment of diseases previously unreachable with existing RNA therapies.
What is AOC 1001 (Del-desiran)?
AOC 1001 (Del-desiran) is Avidity's lead product candidate for treating Myotonic Dystrophy Type 1 (DM1). It has shown promising results in clinical trials and is entering global Phase 3 HARBOR™ trial.
What are the key clinical programs of Avidity Biosciences?
The key clinical programs include AOC 1001 for DM1, AOC 1044 for Duchenne Muscular Dystrophy (DMD) with exon 44 skipping, and AOC 1020 for Facioscapulohumeral Muscular Dystrophy (FSHD).
What designations has AOC 1044 received?
AOC 1044 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA and EMA for its potential to treat Duchenne Muscular Dystrophy (DMD) with exon 44 skipping.
What is the significance of the MARINA-OLE™ trial?
The MARINA-OLE™ trial demonstrated that AOC 1001 (Del-desiran) can reverse disease progression in Myotonic Dystrophy Type 1 (DM1) patients, showing improvements in key metrics such as video hand opening time (vHOT) and muscle strength.
What other areas is Avidity Biosciences expanding into?
In addition to rare muscle diseases, Avidity Biosciences is expanding its pipeline to include cardiology and immunology programs through internal discovery efforts and key partnerships.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in San Diego, CA.
How is Avidity Biosciences funded?
Avidity Biosciences is supported by top-tier investors and partnerships, recently completing an oversubscribed equity raise of $400 million, securing its financial position to fund operations into late 2026.
How can I learn more about Avidity Biosciences?
For more information, visit their official website at www.aviditybiosciences.com.
Avidity Biosciences, Inc.
Nasdaq:RNA
RNA Rankings
RNA Stock Data
5.18B
112.41M
4.83%
106.29%
12.29%
Biotechnology
Pharmaceutical Preparations
United States of America
SAN DIEGO